MX382904B - Combinaciones de fármacos para tratar mieloma múltiple. - Google Patents

Combinaciones de fármacos para tratar mieloma múltiple.

Info

Publication number
MX382904B
MX382904B MX2017001490A MX2017001490A MX382904B MX 382904 B MX382904 B MX 382904B MX 2017001490 A MX2017001490 A MX 2017001490A MX 2017001490 A MX2017001490 A MX 2017001490A MX 382904 B MX382904 B MX 382904B
Authority
MX
Mexico
Prior art keywords
multiple myeloma
treatment
drug combinations
inhibitor
combination
Prior art date
Application number
MX2017001490A
Other languages
English (en)
Spanish (es)
Other versions
MX2017001490A (es
Inventor
Dana T Aftab
Peter Lamb
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2017001490A publication Critical patent/MX2017001490A/es
Publication of MX382904B publication Critical patent/MX382904B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2017001490A 2014-08-05 2015-08-05 Combinaciones de fármacos para tratar mieloma múltiple. MX382904B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033386P 2014-08-05 2014-08-05
PCT/US2015/043825 WO2016022697A1 (en) 2014-08-05 2015-08-05 Drug combinations to treat multiple myeloma

Publications (2)

Publication Number Publication Date
MX2017001490A MX2017001490A (es) 2017-05-11
MX382904B true MX382904B (es) 2025-03-13

Family

ID=53836256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001490A MX382904B (es) 2014-08-05 2015-08-05 Combinaciones de fármacos para tratar mieloma múltiple.

Country Status (13)

Country Link
US (1) US11065240B2 (cg-RX-API-DMAC7.html)
EP (1) EP3177311B1 (cg-RX-API-DMAC7.html)
JP (2) JP6892381B2 (cg-RX-API-DMAC7.html)
KR (1) KR102634247B1 (cg-RX-API-DMAC7.html)
CN (1) CN106573042A (cg-RX-API-DMAC7.html)
AU (1) AU2015301097B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017002318A2 (cg-RX-API-DMAC7.html)
CA (1) CA2957466C (cg-RX-API-DMAC7.html)
EA (1) EA034992B1 (cg-RX-API-DMAC7.html)
MA (1) MA40457A (cg-RX-API-DMAC7.html)
MX (1) MX382904B (cg-RX-API-DMAC7.html)
UA (1) UA121482C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016022697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2015218236B2 (en) 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
KR102634247B1 (ko) 2014-08-05 2024-02-05 엑셀리시스, 인코포레이티드 다발성 골수종을 치료하기 위한 약물 병용물
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
WO2019053611A1 (en) * 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
WO2023222946A1 (en) 2022-05-18 2023-11-23 Fermion Oy Process for the preparation of cabozantinib
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6402215B1 (en) * 1996-05-21 2002-06-11 American Moto Products, Inc. Vehicle cargo bed extender
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
CA2603748A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
NZ592827A (en) 2008-11-13 2013-06-28 Exelixis Inc Methods of preparing quinoline derivatives
JP2012511017A (ja) 2008-12-04 2012-05-17 エグゼリクシス， インコーポレイテッド キノリン誘導体の調製方法
PT2387563E (pt) 2009-01-16 2013-03-25 Exelixis Inc Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro
KR20120051702A (ko) 2009-07-17 2012-05-22 엑셀리시스, 인코포레이티드 Ｎ-〔３-플루오로-４-(｛６-(메틸옥시)-７-〔(３-모르폴린-４-일프로필)옥시〕퀴놀린-４-일｝옥시)페닐〕-ｎ''-(４-플루오로페닐)시클로프로판-１,１-디카르복사미드의 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2531509B1 (en) * 2010-02-03 2016-10-05 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
SG184040A1 (en) 2010-03-12 2012-10-30 Exelixis Inc Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
HUE057184T2 (hu) 2010-07-16 2022-04-28 Exelixis Inc C-MET modulátor gyógyszerészeti készítmények
US20140186407A9 (en) 2010-07-16 2014-07-03 Exelixis Inc. C-Met Modulator Pharmaceutical Compositions
CA2812753A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
CN103402505A (zh) 2010-09-27 2013-11-20 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
WO2012064967A2 (en) * 2010-11-10 2012-05-18 Cedars-Sinai Medical Center Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
WO2012071321A1 (en) 2010-11-22 2012-05-31 Glaxosmithkline Llc Method of treating cancer
KR102030447B1 (ko) 2011-02-10 2019-11-08 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
IN2014CN02971A (cg-RX-API-DMAC7.html) 2011-10-20 2015-07-03 Exelixis Inc
KR20140088610A (ko) 2011-11-08 2014-07-10 엑셀리시스, 인코포레이티드 암을 치료하기 위한 met 및 vegf의 이중 저해제
CA2863986A1 (en) * 2012-02-06 2013-08-15 The Regents Of The University Of California Emp2 regulates angiogenesis in cancer cells through induction of vegf
CN103304552B (zh) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
WO2014039971A1 (en) 2012-09-07 2014-03-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
EP2970126B1 (en) 2013-03-15 2019-03-06 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
US20160082019A1 (en) 2013-04-04 2016-03-24 Exelixis, Inc. Drug Combinations to Treat Cancer
AU2015218236B2 (en) 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
CA2946416C (en) 2014-04-25 2022-07-19 Exelixis, Inc. Method of treating lung adenocarcinoma
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
KR102634247B1 (ko) 2014-08-05 2024-02-05 엑셀리시스, 인코포레이티드 다발성 골수종을 치료하기 위한 약물 병용물
US20170224670A1 (en) 2014-10-14 2017-08-10 Exelixis, Inc. Drug Combination to Treat Melanoma

Also Published As

Publication number Publication date
EA201790312A1 (ru) 2017-06-30
UA121482C2 (uk) 2020-06-10
BR112017002318A2 (pt) 2018-07-17
EP3177311A1 (en) 2017-06-14
JP2020002179A (ja) 2020-01-09
MA40457A (fr) 2017-06-14
JP2017526662A (ja) 2017-09-14
AU2015301097A1 (en) 2017-03-02
AU2015301097B2 (en) 2021-03-04
EA034992B1 (ru) 2020-04-15
MX2017001490A (es) 2017-05-11
CA2957466C (en) 2023-10-17
KR20170031786A (ko) 2017-03-21
CA2957466A1 (en) 2016-02-11
KR102634247B1 (ko) 2024-02-05
CN106573042A (zh) 2017-04-19
WO2016022697A1 (en) 2016-02-11
US11065240B2 (en) 2021-07-20
JP6892381B2 (ja) 2021-06-23
EP3177311B1 (en) 2024-10-30
EP3177311C0 (en) 2024-10-30
US20170224672A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
IL254722A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
IL249065A0 (en) Combination therapies for the treatment of cancer
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
IL256209A (en) Novel cannabinoid combination therapies for multiple myeloma (mm)
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
BR112017008399A2 (pt) abordagem de imunoterapia de combinação para tratamento de câncer
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
IL258521B1 (en) Combination therapy for the treatment of cancer
LT3371165T (lt) Btk inhibitorius, naudojamas vėžiui gydyti
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX375737B (es) Imidazopirazinonas como inhibidores de pde1.
EA201991818A1 (ru) Лечение рака
LT3353177T (lt) Tricikliniai heterociklai, skirti vėžio gydymui
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
IL264589A (en) Combination therapy for the treatment of pancreatic cancer
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين